This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Horizon Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Tim Walbert

Chief Executive Officer (CEO)

US$20.1m

Compensación total

Porcentaje del salario del CEO	6.4%
Permanencia del CEO	14.8yrs
Participación del CEO	0.4%
Permanencia media de la dirección	1.7yrs
Promedio de permanencia en la Junta Directiva	8.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Tim Walbert en comparación con los beneficios de Horizon Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2022	US$20m	US$1m	US$521m
Sep 30 2022	n/a	n/a	US$574m
Jun 30 2022	n/a	n/a	US$765m
Mar 31 2022	n/a	n/a	US$862m
Dec 31 2021	US$21m	US$1m	US$534m
Sep 30 2021	n/a	n/a	US$552m
Jun 30 2021	n/a	n/a	US$518m
Mar 31 2021	n/a	n/a	US$280m
Dec 31 2020	US$22m	US$1m	US$390m
Sep 30 2020	n/a	n/a	US$792m
Jun 30 2020	n/a	n/a	US$517m
Mar 31 2020	n/a	n/a	US$592m
Dec 31 2019	US$14m	US$1m	US$573m
Sep 30 2019	n/a	n/a	US$82m
Jun 30 2019	n/a	n/a	US$97m
Mar 31 2019	n/a	n/a	US$77m
Dec 31 2018	US$17m	US$1m	-US$38m
Sep 30 2018	n/a	n/a	-US$178m
Jun 30 2018	n/a	n/a	-US$275m
Mar 31 2018	n/a	n/a	-US$460m
Dec 31 2017	US$2m	US$1m	-US$350m
Sep 30 2017	n/a	n/a	-US$495m
Jun 30 2017	n/a	n/a	-US$437m
Mar 31 2017	n/a	n/a	-US$212m
Dec 31 2016	US$2m	US$950k	-US$166m

Compensación vs. Mercado: Tim's total compensation ($USD20.10M) is above average for companies of similar size in the BR market ($USD5.00M).

Compensación vs. Ingresos: Tim's compensation has been consistent with company performance over the past year.

CEO

Tim Walbert (55 yo)

14.8yrs

Permanencia

US$20,103,869

Compensación

Mr. Timothy P. Walbert, also known as Tim, is Director of Century Therapeutics, Inc. from October 2022. He had been the Chairman of the Board at Exicure, Inc. since April 2020 until February 4, 2022 and ha...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Timothy Walbert	Chairman	14.8yrs	US$20.10m	0.38% $ 503.0m
Aaron Cox	Executive VP of Finance & CFO	less than a year	US$7.17m	0.00012% $ 157.7k
Sean Clayton	Executive VP & General Counsel	1.1yrs	US$10.87m	0.0036% $ 4.7m
Paul Hoelscher	Advisor	less than a year	US$1.82m	0.081% $ 107.1m
Andy Pasternak	Executive VP & Chief Strategy Officer	3.3yrs	US$6.75m	0.025% $ 32.4m
Elizabeth Thompson	Executive Vice President of Research & Development	2yrs	US$8.48m	0.0064% $ 8.4m
Patrick McIlvenny	Senior VP & Chief Accounting Officer	less than a year	sin datos	0.0028% $ 3.6m
Tina Ventura	Senior VP & Chief Investor Relations Officer	no data	sin datos	sin datos
Geoffrey Curtis	Executive VP of Corporate Affairs & Chief Communications Officer	7.3yrs	sin datos	sin datos
Jane Gonnerman	Senior VP of Corporate Development & Chief of Staff	1.4yrs	sin datos	sin datos
Irina Konstantinovsky	Executive VP	5.5yrs	US$2.31m	sin datos
Jeffrey Sherman	Executive VP & Chief Medical Officer	no data	US$5.86m	0.10% $ 136.2m

1.7yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: H1ZN34's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Timothy Walbert	Chairman	14.8yrs	US$20.10m	0.38% $ 503.0m
Michael Grey	Lead Independent Director	11.5yrs	US$551.24k	0.032% $ 42.3m
William Daniel	Independent Director	8.5yrs	US$522.49k	0.034% $ 44.6m
Jeff Himawan	Independent Director	15.7yrs	US$504.36k	0.024% $ 31.5m
Gino Santini	Independent Director	11yrs	US$494.99k	0.032% $ 41.8m
H. Watkins	Independent Director	8.9yrs	US$506.24k	0.040% $ 52.5m
James Shannon	Independent Director	5.6yrs	US$510.61k	0.019% $ 24.7m
Susan Mahony	Independent Director	3.6yrs	US$514.36k	0.0073% $ 9.6m
Pascale Witz	Independent Director	5.6yrs	US$496.24k	0.019% $ 25.3m

8.9yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: H1ZN34's board of directors are considered experienced (8.9 years average tenure).

This company listing is no longer active

Horizon Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Horizon Therapeutics plc Appoints Sean Clayton Executive Vice President

Horizon Therapeutics Public Limited Company, Annual General Meeting, Apr 29, 2021

Horizon Therapeutics Public Limited Company Announces Executive Appointments

Horizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer

Recent updates

Horizon Therapeutics Public Limited Company to Report Q2, 2023 Results on Aug 08, 2023

Horizon Therapeutics plc Announces New Analysis of MRI Findings Shows UPLIZNA®? (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People with Neuromyelitis Optica Spectrum Disorder

Horizon Therapeutics plc Announces Tepezza® (Teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease

Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (Optic-J) in Japan

Horizon Therapeutics plc Announces Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration

Horizon Therapeutics plc Announces the Publication of New Analysis from the N-MOmentum Clinical Trial of UPLIZNA Demonstrating the Utility of A Robust Assay Process

Horizon Therapeutics plc Announces Data from the Teprotumumab Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease

Horizon Therapeutics plc Announces the Publication of New Data from the Phase 3 N-MOmentum Pivotal Trial of UPLIZNA

Horizon Therapeutics plc Announces Presentations At the 2023 Eular European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’S Syndrome

Horizon Therapeutics Public Limited Company to Report Q4, 2022 Results on Mar 01, 2023

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus

Amgen Inc. (NasdaqGS:AMGN) entered into a transaction agreement to acquire Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) for $27.1 billion.

Amgen Reportedly in Advanced Talks to Buy Horizon Therapeutics

Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (Optic-J) in Japan Evaluating Tepezza® for the Treatment of Active Thyroid Eye Disease

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Horizon Therapeutics Public Limited Company Announces Data Support the Use of KRYSTEXXA (Pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People with Mild-To-Moderate Chronic Kidney Disease

Horizon Therapeutics Public Limited Company Revises Earnings Guidance for the Full Year 2022

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

Horizon Therapeutics plc Announces New Data from Two Analyses of the Uplizna Phase 3 Pivotal Trial Presented At the 38(Th) Congress of the European Committee for Treatment and Research in Multiple Sclerosis (Ectrims 2022), Oct. 26-28 in Amsterdam

Horizon Therapeutics Public Limited Company to Report Q3, 2022 Results on Nov 02, 2022

Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (Teprotumumab-Trbw) in Adults with Chronic/Low Clinical Activity Score (Cas) Thyroid Eye Disease (Ted)

Horizon Therapeutics plc Announces Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint

Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) announces an Equity Buyback for $500 million worth of its shares.

Horizon Therapeutics Public Limited Company Reports Impairment of Goodwill for the Second Quarter Ended June 30, 2022

FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy

Horizon Therapeutics Public Limited Company to Report Q2, 2022 Results on Aug 03, 2022

Horizon Therapeutics Public Limited Company Announces New Analysis Finds UPLIZNA (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon Therapeutics plc Submits Regulatory Filing for Uplizna® (Inebilizumab) in Brazil

Horizon Therapeutics Public Limited Company Announces Results of A New Analysis Examining Rates of Hyperglycemia Among Patients Treated with TEPEZZA for TED Compare to Placebo in the Phase 2 and OPTIC Phase 3 Clinical Trials

Horizon Therapeutics plc Announces Analysis from the Phase 3 N-Momentum Study Demonstrates the Effectiveness of Uplizna(R) (Inebilizumab-Cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (Hzn-7734) for the Treatment of Alopecia Areata

Horizon Therapeutics Public Limited Company Provides Earnings Guidance for the Full Year 2022

Horizon Therapeutics plc Receives European Commission Approval of Uplizna (Inebilizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder

Horizon Therapeutics Public Limited Company to Report Q1, 2022 Results on May 04, 2022

Horizon Therapeutics plc Announces Presentation of A Post-Hoc Analysis from the N-Momentum Phase 3 Pivotal Trial of UPLIZNA

Horizon Therapeutics plc Provides Earnings Guidance for the Full Year 2022

Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)

Horizon Therapeutics plc Appoints Sean Clayton Executive Vice President

Horizon Therapeutics Public Limited Company Announces Results from a New Post-Marketing Safety Analysis of Hearing Events Associated with Tepezza for the Treatment of Thyroid Eye Disease

Horizon Therapeutics Public Limited Company to Report Q4, 2021 Final Results on Mar 01, 2022

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Idiopathic Pulmonary Fibrosis

Horizon Therapeutics plc Announces That A New Post Hoc Analysis of the UPLIZNA N-Momentum Phase 2/3 Pivotal Trial

Horizon Therapeutics Public Limited Company Announces Data Showing UPLIZNA Also Produces Rapid and Sustained B-Cell Depletion in African Americans with Neuromyelitis Optica Spectrum Disorder

Horizon Therapeutics plc Initiates Randomized Controlled Clinical Trial Evaluating TEPEZZA® (Teprotumumab-Trbw) for the Treatment of Chronic (Inactive) Thyroid Eye Disease (TED)

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus

Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from Russell 2500 Growth Index

Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) entered into a definitive agreement to acquire Sterile Fill and Finish Manufacturing Facility in Waterford, Ireland from EirGen Pharma Ltd. for $65 million.

Horizon Therapeutics plc Presents New Data on Robust Pipeline

Horizon Therapeutics plc Initiates ADVANCE Trial Evaluating KRYSTEXXA (pegloticase injection) with Methotrexate for People Who Previously Developed Anti-Drug Antibodies on KRYSTEXXA Monotherapy

Horizon Therapeutics plc Announces the Publication of A New Analysis of the Pivotal Phase 2/3 N-MOmentum trial for UPLIZNA

Horizon Therapeutics Public Limited Company Announces Impairment Charges for the First Quarter Ended March 31, 2021

Horizon Therapeutics Public Limited Company, Annual General Meeting, Apr 29, 2021

Horizon Therapeutics Public Limited Company Announces Executive Appointments

Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and Outcomes

Horizon Therapeutics Public Limited Company Provides Sales Guidance for the Year 2020

Horizon Therapeutics plc Announces Short-Term TEPEZZA (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine Production

Horizon Therapeutics plc Announces New Data Build on Growing Evidence Supporting TEPEZZA® (teprotumumab-trbw) Efficacy in Thyroid Eye Disease (TED), Including in Patients With Less Severe Disease and Longer Disease Duration

Horizon Therapeutics Public Limited Company Revises Sales Guidance for the Full Year 2020

Horizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad